Abstract Library

#4231 Analysis of AI-based clinical trial search tool usage reveals motivations of neuroendocrine tumors patients in searching for trials

Introduction: It is challenging to recruit neuroendocrine tumors (NETs) patients to clinical trials. Delays in trial recruitment are detrimental to progress in clinical research. One potential reason for delays is that many patients report not being offered trials.

Conference:

Presenting Author: Mailman J

Authors: Ralic D, Mailman J,

Keywords: AI, patient engagement, clinical research, NET, clinical trials,

#3464 Digital quantification of somatostatin receptor subtype 2 immunostaining in pancreatic neuroendocrine tumors and GH-secreting adenoma: A validation study

Introduction: Somatostatin receptor subtype 2 (SST2) immunostaining (IHC) is routinely performed in neuroendocrine tumors (NET) and recommended in acromegaly guidelines. No univocal score of SST2 IHC has been validated yet.

Conference:

Presenting Author: Campana C

Authors: Campana C, van Koetsveld P, Iyer A, van Velthuysen M, van den Dungen E,

Keywords: SST2, digital image analysis, panNET, staining intensity, percentage of positive cell,

#1737 The Role of MAPK-Signalling in Pancreatic Neuroendocrine Cancer

Introduction: Upon diagnosis, 65% of pNET patients suffer from metastatic or locally unresectable disease. The receptor tyrosine kinase inhibitor sunitinib and the mTOR inhibitor everolimus have set precedence for successful targeted therapies in pNET disease. However, response prediction and treatment alternatives still do not meet medical needs. Recent studies revealed mutations in RAS oncogenes in a fraction of tumours, emphasising a potential role of the MAPK pathway as therapeutic target.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Hoffmann J, Corbett L, Detjen K, Thedieck K, Sers C,

Keywords: pancreatic neuroendocrine tumors, MAPK pathway,